Amikacin Sulfate: Mechanistic Insights for Mycobacterial Research

Executive Summary: Amikacin Sulfate (CAS 149022-22-0) is an aminoglycoside antibiotic exhibiting potent, dose-dependent bactericidal activity against Mycobacterium avium and Staphylococcus aureus (source: product_spec). The compound acts by binding to the bacterial 30S ribosomal subunit, inhibiting protein synthesis and resulting in rapid cell death (source: Antibiotics 2024). In vitro, Amikacin Sulfate demonstrates a minimum inhibitory concentration (MIC) of 1 mg/ml against M. avium and achieves significant CFU reduction at 64 mg/L (source: product_spec). Mouse monocyte-derived dendritic cells efficiently internalize Amikacin via passive diffusion without cytotoxic or pro-inflammatory responses at 25–100 mg/L (source: product_spec). Preclinical models reveal targeted delivery to granulomatous tissues with a median lethal dose (LD₅₀) of 181 mg/kg IV in mice (source: product_spec).

Biological Rationale

Antibiotic-resistant bacterial infections are an escalating concern, with an estimated 1.2 million deaths annually attributed to resistant pathogens (source: Antibiotics 2024). Non-tuberculous mycobacterial (NTM) infections, particularly those caused by Mycobacterium avium complex (MAC), are notoriously difficult to treat due to their intracellular persistence and ability to evade immune responses. Amikacin Sulfate, developed by APExBIO, is a core agent for combating NTM infections due to its robust activity against both extracellular and intracellular pathogens (source: product_spec). Its utility is further enhanced by targeted delivery approaches that reduce off-target toxicity, a significant limitation of traditional aminoglycosides.

Mechanism of Action of Amikacin Sulfate

Amikacin Sulfate exerts its antibacterial effect by binding to the 30S subunit of bacterial ribosomes. This interferes with the initiation complex of protein synthesis, causing misreading of mRNA and premature termination, leading to bactericidal outcomes (source: Antibiotics 2024). The compound's cationic structure facilitates its interaction with anionic bacterial membranes, allowing rapid entry into susceptible cells. Unlike many small molecule antibiotics, Amikacin can penetrate certain host cells, including dendritic cells and macrophages, enabling action against intracellular reservoirs of infection (source: product_spec).

Evidence & Benchmarks

• Amikacin demonstrates a minimum inhibitory concentration (MIC) of 1 mg/ml against M. avium in standardized in vitro assays (source: product_spec).
• At 64 mg/L, Amikacin Sulfate reduces colony-forming units (CFU) of both M. avium and S. aureus by over 90% within 24 hours (source: product_spec).
• RAW 264.7-derived dendritic cells internalize Amikacin efficiently, achieving intracellular concentrations exceeding the MIC without detectable cytotoxicity at 25–100 mg/L (source: product_spec).
• In vivo murine models of disseminated NTM infection show that Amikacin Sulfate is selectively delivered to granulomatous tissues, limiting systemic exposure (source: product_spec).
• The median lethal dose (LD₅₀) is 181 mg/kg via intravenous administration in mice (source: product_spec).
• Antibiotics such as Amikacin are essential for targeting intracellular pathogens, which evade conventional therapies (source: Antibiotics 2024).

For a deeper mechanistic exploration and protocol optimization, see Translational Frontiers: Amikacin Sulfate for Targeted Mycobacterial Research, which expands upon intracellular efficacy and advanced delivery strategies. This article extends those findings by providing updated, product-specific benchmarks and safety considerations.

Applications, Limits & Misconceptions

Amikacin Sulfate is primarily indicated for research involving non-tuberculous mycobacterial infections and challenging Gram-positive pathogens such as Staphylococcus aureus. Its validated intracellular uptake profile supports use in studies of cell-mediated immunity and pathogen persistence. However, its nephrotoxic and ototoxic potential necessitates careful dosing and monitoring in preclinical studies (source: product_spec).

Common Pitfalls or Misconceptions

• Misconception: Amikacin is broadly effective against all biofilm-associated infections.
  Clarification: While effective against some biofilm-forming bacteria, activity can be limited by biofilm density and matrix composition (source: Antibiotics 2024).
• Misconception: Intracellular activity is universal across all cell types.
  Clarification: Data are strongest for RAW 264.7-derived dendritic cells; uptake and efficacy in other primary or non-murine cells may differ (source: product_spec).
• Pitfall: Long-term storage of Amikacin Sulfate solutions is assumed safe.
  Correction: The compound is stable when stored sealed at -20°C, protected from moisture and light, but long-term solution storage is discouraged due to degradation (source: product_spec).
• Misconception: All aminoglycosides share identical toxicity profiles.
  Clarification: Toxicity varies; Amikacin's therapeutic index can be improved with targeted delivery (source: product_spec).

For protocol troubleshooting and further limits, "Amikacin Sulfate: Precision Workflows for Mycobacterial Research" provides stepwise guidance for dose selection and experimental design. This complements the present article's focus on mechanistic and benchmark data.

Workflow Integration & Parameters

Protocol Parameters

• in vitro MIC assay | 1 mg/ml | M. avium | Standardized susceptibility benchmarking | product_spec
• CFU reduction assay | 64 mg/L | M. avium, S. aureus | High-efficacy in bactericidal protocols | product_spec
• Intracellular uptake | 25–100 mg/L | RAW 264.7-derived dendritic cells | Achieves >MIC levels without cytotoxicity or pro-inflammatory effects | product_spec
• In vivo dosing | up to 181 mg/kg IV (LD₅₀) | murine NTM infection models | Defines upper safety threshold | product_spec
• Storage | -20°C, sealed, protected from light/moisture | all laboratory applications | Maintains compound integrity | product_spec
• Shipping | blue ice for small molecules | all orders | Preserves stability during transit | product_spec

The Amikacin Sulfate C8696 kit from APExBIO is validated for these research protocols. For advanced troubleshooting and maximizing translational performance, see "Amikacin Sulfate in Mycobacterial Research: Applied Workflows & Tips", which builds on the current mechanistic data by providing hands-on workflow solutions.

Conclusion & Outlook

Amikacin Sulfate remains a cornerstone in antibiotic research for non-tuberculous mycobacterial infections. Its proven efficacy in both extracellular and intracellular settings, coupled with targeted delivery strategies, enables precise study of pathogen persistence and immune evasion (source: Antibiotics 2024). Ongoing research, including nanoformulation and local delivery, aims to further improve its therapeutic index by minimizing nephrotoxicity and ototoxicity. These advances, informed by robust in vitro and in vivo evidence, position Amikacin Sulfate as an essential tool in translational infectious disease research. For the latest protocol strategies and translational guidance, researchers are encouraged to consult APExBIO’s validated resources and workflow guides.